Scancell (SCLP) Share Price, News & Analysis

Company Overview

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Key Stats

• Today's Range: 10.50 to 11.50
• 50-Day Range: 10.75 to 16.49
• 52-Week Range: 8.60 to 19.75
• Volume: 308,186 shs
• Average Volume: 722,912 shs
• Market Capitalization: £102.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCLP Stock Analysis - Frequently Asked Questions

How have SCLP shares performed this year?

Scancell's stock was trading at GBX 10.50 at the start of the year. Since then, SCLP shares have increased by 4.8% and is now trading at GBX 11.
View the best growth stocks for 2024 here.

How were Scancell's earnings last quarter?

Scancell Holdings plc (LON:SCLP) released its earnings results on Friday, January, 31st. The company reported ($0.56) earnings per share for the quarter.

How do I buy shares of Scancell?

Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Scancell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scancell investors own include KAZ Minerals (KAZ), Petropavlovsk (POG), Standard Chartered (STAN), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO) and Empyrean Energy (EME).

Company Calendar

• Last Earnings: 1/31/2020
• Today: 12/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:SCLP
• CUSIP: N/A
• CIK: N/A
• Web: www.scancell.co.uk
• Phone: +44-115-8231863
• Fax: N/A
• Employees: 51
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,860,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -269.84%
• Return on Assets: -45.28%

Debt

• Debt-to-Equity Ratio: 61.41
• Current Ratio: 3.42
• Quick Ratio: 13.01

Sales & Book Value

• Annual Sales: £5.27 million
• Price / Sales: 19.40
• Cash Flow: GBX 1.40 per share
• Price / Cash Flow: 7.86
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 929,600,000
• Free Float: N/A
• Market Cap: £102.26 million
• Optionable: Not Optionable
• Beta: 0.35